|
End-of-day quote
Pakistan S.E.
19/08/2026
|
5-day change | 1st Jan Change | ||
| 340.44 PKR | -0.81% |
|
-1.44% | -12.66% |
Company Valuation: GlaxoSmithKline Pakistan Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 126,403 | 124,132 | 108,419 | - | - |
| Change | - | -1.8% | -12.66% | - | - |
| Enterprise Value (EV) | 126,403 | 124,132 | 108,419 | 108,419 | 108,419 |
| Change | - | -1.8% | -12.66% | 0% | 0% |
| P/E | 19.3x | 12.4x | 9.88x | 8.43x | 7.52x |
| PBR | - | 3.69x | 2.49x | 2.15x | 1.88x |
| PEG | - | 0.2x | 1.04x | 0.5x | 0.6x |
| Capitalization / Revenue | - | 1.88x | 1.58x | 1.45x | 1.33x |
| EV / Revenue | - | 0x | 1.58x | 1.45x | 1.33x |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | 17 | 18.37 | 20.81 | 23.5 |
| Rate of return | - | 4.36% | 5.4% | 6.11% | 6.9% |
| EPS 2 | 20.52 | 31.48 | 34.47 | 40.39 | 45.27 |
| Distribution rate | - | 54% | 53.3% | 51.5% | 51.9% |
| Net sales 1 | - | 65,901 | 68,813 | 74,577 | 81,779 |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Net income 1 | 6,536 | 10,025 | 10,490 | 12,420 | 14,268 |
| Net Debt | - | - | - | - | - |
| Reference price 2 | 396.91 | 389.78 | 340.44 | 340.44 | 340.44 |
| Nbr of stocks (in thousands) | 318,467 | 318,467 | 318,467 | - | - |
| Announcement Date | 24/03/25 | 26/03/26 | - | - | - |
1PKR in Million2PKR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 9.88x | - | - | 5.4% | 391M | ||
| 36.57x | 13.2x | 26.79x | 0.54% | 1,141B | ||
| 30.41x | - | - | 1.96% | 659B | ||
| 33.95x | 7.85x | 16.34x | 2.58% | 470B | ||
| 20.47x | 4.85x | 12.03x | 2.72% | 366B | ||
| 22.39x | 5.8x | 14.38x | 2.75% | 302B | ||
| 21x | 4.33x | 12.29x | 2.03% | 254B | ||
| 27.98x | 7.21x | 12.8x | 2.28% | 239B | ||
| 13.62x | 4.84x | 10.15x | 3.77% | 207B | ||
| -45.1x | 6.51x | 25.42x | 2.23% | 183B | ||
| Average | 17.12x | 6.82x | 16.27x | 2.63% | 382.14B | |
| Weighted average by Cap. | 25.80x | 8.63x | 18.95x | 1.88% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLAXO Stock
- Valuation GlaxoSmithKline Pakistan Limited
Select your edition
All financial news and data tailored to specific country editions
















